Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 05.

353P - Effect of cepharanthine on the stemness of lung squamous cell carcinoma based on network pharmacology and bioinformatics

Date

03 Dec 2022

Session

Poster viewing 05.

Topics

Basic Science

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Jianxiong Deng

Citation

Annals of Oncology (2022) 33 (suppl_9): S1560-S1597. 10.1016/annonc/annonc1134

Authors

J. Deng1, J. Xu2, F. Yu3, F. Qiu4

Author affiliations

  • 1 Oncology Department, Gaoxin Hospital of the First Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
  • 2 Oncology, Gaoxin Hospital of the First Affiliated Hospital of Nanchang University, 330096 - Nanchang/CN
  • 3 Oncology Department, The First Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
  • 4 Oncology, The First Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 353P

Background

Lung squamous cell carcinoma (LUSC) has poor survival prognosis and few clinical treatment options. We urgently need to explore new therapeutic drugs in clinical practice. Cepharanthine (CEP), which has been shown to have anticancer effects in several tumors, but the mechanism of CEP in treating LUSC has not been reported.

Methods

SwissTargetPrediction, PharmMapper and GeneCards were used to identify targets of CEP and LUSC. Further topological analysis was used to obtain hub genes via Cytoscape. Molecular docking was carried out to verify the combination of CEP with hub targets. Based on bioinformatics, we first analyzed the expression and survival of hub targets in LUSC, and further analyzed the correlation between hub targets and cancer stemness, immune cell infiltration and tumor mutation burden (TMB).

Results

A total of 41 targets were identified. Further topological analysis identified 6 hub genes: AURKA, CCNA2, CCNE1, CDK1, CHEK1 and PLK1. Molecular docking analysis showed that CEP had stable binding to all these 6 target proteins. In-depth bioinformatics analysis of these 6 targets showed that high expression of these targets were positively correlated with cancer stemness index, and negatively correlated with tumor infiltrating immune cells. In immune subtype analysis, the expressions of these targets were significantly decreased in inflammatory tumors. In addition, we also found that the expressions of these targets were positively correlated with TMB.

Conclusions

Based on multidisciplinary analysis, we preliminarily identified potential targets of CEP for LUSC treatment and suggested that CEP may play a role in regulating LUSC stemness.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.